Starting clozapine in the community: A UK perspective

CNS Drugs

Volumn 18, Issue 13, 2004, Pages 845-852

  O'Brien, Aileen ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; BLOOD TESTIS BARRIER; CARDIOMYOPATHY; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY; COMMUNITY CARE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UTILIZATION; HEALTH SERVICE; HEMATOLOGIC DISEASE; HISTORY OF MEDICINE; HOME CARE; HOSPITAL; HOSPITAL ADMISSION; HUMAN; HYPERTHERMIA; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL STAFF; MENTAL DISEASE; MENTAL PATIENT; MONITORING; MYOCARDITIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SALIVATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT INDICATION; UNITED KINGDOM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL PROTOCOLS; CLOZAPINE; GREAT BRITAIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RESIDENCE CHARACTERISTICS; RISK; SCHIZOPHRENIA;

EID: 10044285878     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418130-00002     Document Type: Review

References (36)

1. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000; (2): CD000059
2. Duggan A, Warner J, Knapp M, et al. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003; 182: 505-8
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45 (9): 789-96
4. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients: I. Preliminary report. Psychopharmacology (Berl) 1989; 99 Suppl.: S68-72
5. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41 (8): 892-7
6. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156 (7): 990-9
7. Grace J, Bellus SB, Raulin ML, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996; 47 (1): 41-5
8. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337 (12): 809-15
9. Davis J, Chen N, Glick ID. A Meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-6
10. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine: a UK clinic-based study. Br J Psychiatry 1997; 171: 125-30
11. Percudani M, Fattore G, Galletta J, et al. Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Acta Psychiatr Scand 1999; 99 (4): 274-80
12. Serretti A, De Ronchi D, Lorenzi C, et al. New antipsychotics and schizophrenia: a review of efficacy and side-effects. Curr Med Chem 2004; 11 (3): 343-58
13. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60 (1): 82-91
14. Spivak B, Shabash E, Sheitman B, et al. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 2003; 64 (7): 755-60
15. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23 (4): 607-11
16. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000; 20(1): 94-8
17. Albanese MJ, Khantzian EJ, Murphy SL, et al. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994; 151 (5): 780-1
18. Puri BK, Taylor DG, Alcock ME. Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. Br J Clin Pract 1995; 49 (6): 333-4
19. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156 (8): 1164-9
20. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56 (9): 411-7
21. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34 (6): 402-5
22. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59 (3): 103-7
23. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26 (1): 8-11
24. National Institute of Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute of Clinical Excellence, 2002
25. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64 (1): 30-4
26. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11 (1): 25-32
27. Wetterling T. Diabetes mellitus type II: induced by "atypical" neuroleptics? [in German]. Fortschr Neurol Psychiatr 2003; 71 (6): 312-22
28. Johnson CG, Littrell KH, Magill AM. Starting patients on clozapine in a partial hospitalization program. Hosp Community Psychiatry 1994; 45 (3): 264-8
29. Stockwell T, Bolt L, Milner I, et al. Home detoxification for problem drinkers: acceptability to clients, relatives, general practitioners and outcome after 60 days. Br J Addict 1990; 85 (1): 61-70
30. Raistrick D. Management of alcohol detoxification. Adv Psychiatr Treat 2000; 6 (5): 348-55
31. Stein LI, Test MA. Alternative to mental hospital treatment: I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37 (4): 392-7
32. O'Brien A, Firn M. Clozapine initiation in the community. Psychiatric Bulletin 2002; 26: 339-41
33. Out-patient initiation guidelines for Clozaril CD. East Hanover (NJ): Novartis, 2003
34. Committee of Safety in Medicines. Clozapine and cardiac safety: updated advice for prescribers. Curr Probl Pharmacovigilance 2002; 28: 8
35. Haupt DW, Newcomer JW. Hyperglycaemia and antipsychotic medication. J Clin Psychiatry 2001; 62 (27): 15-26
36. Clark NG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601